RIGImmune Logo.jpg
RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024
09 sept. 2024 07h55 HE | RIGImmune
Pre-clinical studies for intranasal RIG-101, a first in class RIG-I agonist, demonstrate potent local innate immune stimulation and pan-viral activity against human rhinovirus, influenza and RSV...
Ancilia_Wordmark_Decorative_no R.png
Ancilia Biosciences Announces Closing of $4.2 Million Financing
17 juil. 2024 07h00 HE | Ancilia Biosciences
Ancilia raised $4.2M to leverage CRISPR’s natural function to create bacterial therapies with immunity against the viruses that limit their effectiveness.
cmi_logo.png
[Latest] Global Crop Protection Chemicals Market Size/Share Worth USD 98.5 Billion by 2032 at a 4.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
13 févr. 2024 11h30 HE | Custom Market Insights
Austin, TX, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Crop Protection Chemicals Market Size, Trends and Insights By Type (Herbicides,...
PDS Biotech Logo.png
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
16 févr. 2023 08h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Logo.png
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
08 févr. 2023 16h00 HE | PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
RIGImmune Logo.jpg
RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments
07 déc. 2022 08h00 HE | RIGImmune
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies Company also...
New Logo.png
Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
27 janv. 2022 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene...
logo.gif
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
20 nov. 2020 09h10 HE | Auris Medical AG
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Moleaer 2020 Logo-01.jpg
Moleaer & ASU confirm nanobubbles produce reactive oxygen species, hydroxyl radicals, known to eliminate hard-to-kill pathogens
26 oct. 2020 12h00 HE | Moleaer Inc.
Carson, CA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Moleaer, a leading nanobubble technology company, in collaboration with Arizona State University’s (ASU) Research Center for Nanotechnology Enabled...
Conduent_Registermark_Horizontal-black (002).png
Coronavirus (COVID-19) Tracking Now Integrated into Conduent Maven® Platform  
05 mars 2020 03h30 HE | Conduent Business Services, LLC
Maven’s COVID-19 tracking software module makes required reporting by state and local health authorities more efficient and cost-effective Company will demonstrate Maven’s capabilities at HIMSS...